Dissociative drugs: effects, mechanisms, common types, and uses

Mechanisms of action

Dissociative drugs act at several different molecular targets. A major group—such as ketamine and phencyclidine (PCP)—are N-methyl-D-aspartate (NMDA) receptor antagonists that reduce the action of glutamate, a principal excitatory neurotransmitter involved in memory, sensory integration and synaptic plasticity. Other dissociatives interact with opioid receptors (including kappa-opioid receptors), sigma receptors, or monoamine systems such as dopamine and serotonin. Some plant-derived agents, for example constituents of Salvia divinorum, have prominent activity at kappa-opioid receptors. For detailed pharmacology and reviews see pharmacology review and mechanisms overview. General discussions of glutamate’s role are available at glutamate resources.

Common substances

• Ketamine — an NMDA receptor antagonist used in human and veterinary anesthesia and increasingly researched for rapid antidepressant effects; information: ketamine information.
• Phencyclidine (PCP) — developed as an anesthetic but withdrawn from routine medical use because of adverse psychological and behavioral effects; background: PCP details.
• Dextromethorphan (DXM) — an over-the-counter cough suppressant that produces dissociative effects in high doses; summary: DXM summary.
• Salvia divinorum — a psychoactive plant whose primary compound acts notably at kappa-opioid receptors and can produce short, intense dissociative episodes; profile: Salvia profile.
• Nitrous oxide — an inhaled agent used in dentistry and obstetrics for analgesia and mild dissociation; notes: nitrous oxide notes.

Medical uses and therapeutic research

Clinically, dissociatives have been used as general anesthetics, procedural sedatives and analgesics. Ketamine is notable for preserving cardiovascular stability at many anesthetic doses and for emerging, controlled uses in low-dose regimens for treatment-resistant depression and acute suicidal ideation. Dextromethorphan remains widely used as a cough suppressant when taken at recommended doses. Research continues into controlled, low-dose administration of dissociatives for psychiatric conditions and chronic pain; summaries of clinical trials and reviews are available at clinical review and treatment research.

Acute effects, risks and long-term harms

Acute effects include sensory distortions (visual and auditory changes), feelings of detachment or floating, reduced pain perception, confusion and unpredictable mood changes. Dangerous acute risks include impaired coordination and judgment that raise the risk of injury, and respiratory depression when dissociatives are mixed with alcohol or other sedatives. Repeated or heavy use has been associated with cognitive changes, urinary tract and bladder damage in frequent high-dose ketamine users, and occasional prolonged psychotic reactions after substances such as PCP. Dependence potential varies by compound and pattern of use. For practical safety and clinical risk information see harm reduction, risk overview and safety guidance.

Harm reduction and clinical considerations

When dissociatives are used recreationally, harm reduction emphasizes known-dose products, avoiding combinations with depressant drugs or alcohol, having sober supervision in case of disorientation, and seeking immediate care for respiratory problems or severe behavioral disturbance. In medical and research settings, careful screening, standardized dosing, monitoring of vital signs and informed consent are essential. Clinical guidelines and best-practice summaries are available at treatment guidelines and safety guidance.

Legal status and policy

Legal classification varies by country and by agent: some dissociatives are prescription-only medicines for approved indications, others are controlled substances, and some plant materials or over-the-counter medicines may be subject to additional regulation. Policy, scheduling and enforcement differ across jurisdictions; readers should consult local regulatory summaries and authoritative portals at legal overview, research portal and policy statement.

Research directions and notable findings

Recent research has focused on rapid antidepressant effects of subanesthetic ketamine, mechanisms of neuroplasticity and glutamatergic modulation, and safer clinical use models for psychiatric indications. Comparative reviews and mechanistic studies can help explain why dissociatives produce both therapeutic and adverse effects; see monoamine studies, glutamate research and comparative reviews. Ongoing clinical trials and translational work are summarized at treatment research and public health portals.

Because the term "dissociative" covers chemically and pharmacologically diverse agents, any evaluation of a specific substance should consider its precise pharmacology, common routes of administration, typical dose ranges, setting of use and legal status. Responsible medical use is distinct from recreational use, and both benefit from reliable, evidence-based information and appropriate supervision.

Further reading and resources

• Introductory overview
• Pharmacology review
• Mechanisms overview
• Clinical review
• Treatment research
• Harm reduction
• Risk overview
• Safety guidance
• Legal overview
• Salvia profile
• Nitrous oxide notes
• Research portal
• Policy statement
• Public health
• Monoamine studies
• Glutamate resources
• Comparative reviews
• Treatment guidelines
• Ketamine information
• PCP details
• DXM summary